Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines

Arthritis Care and Research

Volumn 67, Issue 10, 2015, Pages 1440-1452

  Tunnicliffe, David J ^a,b   Singh Grewal, Davinder ^a   Kim, Siah ^a   Craig, Jonathan C ^a   Tong, Allison ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; VITAMIN D;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DRUG MEGADOSE; HUMAN; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MENTAL DISEASE; MONITORING; NEUROLOGIC DISEASE; OSTEOPOROSIS; PLASMAPHERESIS; PRACTICE GUIDELINE; QUALITY OF LIFE; REPRODUCTIVE HEALTH; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; DISEASE COURSE; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84942133204     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22591     Document Type: Article

References (46)

1. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al., Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7.
2. Lerang K, Gilboe IM, Gran JT., Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. Rheumatology (Oxford) 2012; 51: 663-9.
3. Walsh M, Jayne D, Moist L, Tonelli M, Pannu N, Manns B., Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. Lupus 2010; 19: 628-33.
4. Siedner MJ, Christopher-Stine L, Astor BC, Gelber AC, Fine DM., Screening for proteinuria in patients with lupus: a survey of practice preferences among American rheumatologists. J Rheumatol 2007; 34: 973-7.
5. Brunner H, Klein-Gitelman M, Ying J, Tucker L, Silverman E., Corticosteroid use in childhood-onset systemic lupus erythematosus-practice patterns at four pediatric rheumatology centers. Clin Exp Rheumatol 2009; 27: 155-62.
6. Grimshaw J, Russell I., Achieving health gain through clinical guidelines. I: developing scientifically valid guidelines. Qual Health Care 1993; 2: 243-8.
7. Grimshaw JM, Russell IT., Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317-22.
8. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al., AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839 -E42.
9. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
10. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999; 42: 1785-96.
11. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al., European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-74.
12. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al., EULAR recommendations for the management of systemic lupus erythematosus: report of a task force of the EULAR Standing Committee for international clinical studies including therapeutics. Ann Rheum Dis 2008; 67: 195-205.
13. Calvo-Alen J, Silva-Fernandez L, Ucar-Angulo E, Pego-Reigosa JM, Olive A, Martinez-Fernandez C, et al., SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatología Clínica 2013; 09: 281-96.
14. Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al., Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-67.
15. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al., Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 375-83.
16. Ruiz IG, Espinosa G, Frutos M, Jimenez AJ, Praga M, Pallares L, et al., Diagnosis and treatment of lupus nephritis: consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (SEN). Nefrologia 2012; 32: 1-35.
17. Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, et al., Current state of evidence on "off label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland: a consensus report. Lupus 2012; 21: 386-401.
18. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al., EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-82.
19. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al., Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
20. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD, et al., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
21. Van Tellingen A, Voskuyl A, Vervloet M, Bijl M, de Sevaux R, Berger S, et al., Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Neth J Med 2012; 70: 199-207.
22. Kidney Disease Improving Global Outcomes Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274. URL: http://www.kdigo.org/clinical-practice-guidelines/pdf/KDIGO-GN-Guideline.pdf.
23. Mok CC, Yap DY, Navarra SV, Liu Zh, Zhao Mh, Lu L, et al., Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis 2013; 16: 625-36.
24. Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT., Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol 2013; 9: 687-94.
25. Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, et al., SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010; 10: 55-60.
26. Yu C, Gershwin ME, Chang C., Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014; 48: 10-3.
27. Boumpas D, Balow J., Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622-9.
28. Bose B, Silverman ED, Bargman JM., Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis 2014; 63: 667-76.
29. Gurses AP, Murphy DJ, Martinez EA, Berenholtz SM, Pronovost PJ., A practical tool to identify and eliminate barriers to compliance with evidence-based guidelines. Jt Comm J Qual Patient Saf 2009; 35: 526-32.
30. Saag KG, Yazdany J, Alexander C, Caplan L, Coblyn J, Desai SP, et al., for the American College of Rheumatology Quality Measurement White Paper Development Work Group. Defining quality of care in rheumatology: the American College of Rheumatology white paper on quality measurement. Arthritis Care Res (Hoboken) 2011; 63: 2-9.
31. Dougados M, Betteridge N, Burmester G, Euller-Ziegler L, Guillemin F, Hirvonen J, et al., EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004; 63: 1172-6.
32. Van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M, et al., 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015; 74: 8-13.
33. Grol R., Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001; 39: Suppl 2: II46-54.
34. Mold JW, Fox C, Wisniewski A, Lipman PD, Krauss MR, Harris DR, et al., Implementing asthma guidelines using practice facilitation and local learning collaboratives: a randomized controlled trial. Ann Fam Med 2014; 12: 233-40.
35. Krahn M, Naglie G., The next step in guideline development: incorporating patient preferences. JAMA 2008; 300: 436-8.
36. Nilsen E, Myrhaug H, Johansen M, Oliver S, Oxman A., Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material. Cochrane Database Syst Rev 2006; 3: CD004563.
37. Schunemann H, Fretheim A, Oxman AD., Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst 2006; 4: 22.
38. Eccles MP, Grimshaw JM, Shekelle P, Schunemann HJ, Woolf S., Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest. Imp Sci 2012; 7: 60.
39. Tong A, Lopez-Vargas P, Howell M, Phoon R, Johnson D, Campbell D, et al., Consumer involvement in topic and outcome selection in the development of clinical practice guidelines. Health Expect 2012; 15: 410-23.
40. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al., GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-6.
41. Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli FM, et al., Treatment for lupus nephritis. Cochrane Database Syst Rev 2012; 12;12: CD002922.
42. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, et al., Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61: 74-87.
43. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, Le Guern V, Leroux G, Marra D, et al., Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013; 27: 329-40.
44. Bruce IN, Gladman DD, Urowitz MB., Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 2000; 13: 406-8.
45. Costedoat-Chalumeau N., International prospective study on adherence to treatment in patients with active systemic lupus erythematosus (TPASLE). 2011. URL: http://clinicaltrials.gov/show/NCT01509989.
46. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al., Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 11: CD000011.